Targeted delivery of melittin to cancer cells by AS1411 anti-nucleolin aptamer

被引:40
作者
Rajabnejad, Seyed Hossein [1 ,2 ]
Mokhtarzadeh, Ahad [3 ,4 ]
Abnous, Khalil [1 ]
Taghdisi, Seyed Mohammad [5 ]
Ramezani, Mohammad [1 ]
Razavi, Bibi Marjan [5 ]
机构
[1] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Pharmaceut Res Ctr, Mashhad, Iran
[2] Res Inst Food Sci & Technol, Mashhad, Iran
[3] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran
[4] Higher Educ Inst Rab Rashid, Dept Biotechnol, Tabriz, Iran
[5] Mashhad Univ Med Sci, Sch Pharm, Targeted Drug Delivery Res Ctr, Mashhad, Iran
关键词
Cancer; aptamer; targeted delivery system; melittin; BEE VENOM; PEPTIDE; INHIBITION; PROGRESS;
D O I
10.1080/03639045.2018.1427760
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Melittin, a small water-soluble cationic amphipathic alpha-helical linear peptide, consisted of 26 amino acids, is the honeybee venom major constituent. Several reports have proved the lytic and apoptotic effects of melittin in several cancerous cell lines. In this study, we aimed to fabricate an AS1411 aptamer-melittin to specifically deliver melittin to nucleolin positive cells (A549). Melittin was covalently attached to antinucleolin aptamer (AS1411) and its toxicity in A549 (nucleolin positive) and L929 (nucleolin negative) was studied using MTT and Annexin V flow cytometry methods. Aptamer-melittin conjugate formation was confirmed by gel electrophoresis. Hemolytic effect of aptamer-melittin conjugate was compared to melittin alone. The aptamer-melittin conjugate showed efficient cell uptake and was more cytotoxic in A549 cells than melittin (p < .001). This complex was less toxic in control cells. Competitive inhibition assay confirmed that aptamer-melittin complex delivery occurred through receptor-ligand interaction on the cell surface. Moreover, aptamer-melittin showed a significantly less hemolytic activity as compared with free melittin. This study showed that melittin could be specifically delivered to A549 cells when it was covalently conjugated to antinucleolin aptamer (AS1411) in vitro. This system can reduce the cytotoxic effects of melittin on cells with no nucleolin receptor overexpression which comprise most of normal cells such as L929 cells.
引用
收藏
页码:982 / 987
页数:6
相关论文
共 37 条
[1]   Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro [J].
Alibolandi, Mona ;
Ramezani, Mohammad ;
Sadeghi, Fatemeh ;
Abnous, Khalil ;
Hadizadeh, Farzin .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 479 :241-251
[2]   Synthesis of AS1411-Aptamer-Conjugated CdTe Quantum Dots with High Fluorescence Strength for Probe Labeling Tumor Cells [J].
Alibolandi, Mona ;
Abnous, Khalil ;
Ramezani, Mohammad ;
Hosseinkhani, Hossein ;
Hadizadeh, Farzin .
JOURNAL OF FLUORESCENCE, 2014, 24 (05) :1519-1529
[3]   Oriented Surface Immobilization of Antibodies at the Conserved Nucleotide Binding Site for Enhanced Antigen Detection [J].
Alves, Nathan J. ;
Kiziltepe, Tanyel ;
Bilgicer, Basar .
LANGMUIR, 2012, 28 (25) :9640-9648
[4]   Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer [J].
Bates, Paula J. ;
Laber, Damian A. ;
Miller, Donald M. ;
Thomas, Shelia D. ;
Trent, John O. .
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2009, 86 (03) :151-164
[5]   Silver staining of proteins in polyacrylamide gels [J].
Chevallet, Mireille ;
Luche, Sylvie ;
Rabilloud, Thierry .
NATURE PROTOCOLS, 2006, 1 (04) :1852-1858
[6]   Nanotechnological carriers for cancer chemotherapy: The state of the art [J].
Estanqueiro, Marilene ;
Amaral, Maria Helena ;
Conceicao, Jaime ;
Sousa Lobo, Jose Manuel .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2015, 126 :631-648
[7]   Melittin: A lytic peptide with anticancer properties [J].
Gajski, Goran ;
Garaj-Vrhovac, Vera .
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2013, 36 (02) :697-705
[8]  
Ginisty H, 1999, J CELL SCI, V112, P761
[9]   Cancer prevention: major initiatives and looking into the future [J].
Gotay, Carolyn Cook .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2010, 10 (02) :143-154
[10]  
Guo Y-q, 2015, CHINESE MED, V10, P1